Literature DB >> 11226518

MUC1 expression in plasmacytoma.

S Paydaş1, B Sahin, G Gönlüşen, B Hazar, S Zorludemir.   

Abstract

Plasmacytoma (Pm) is a plasma cell (PC) neoplasia consisting of PCs and some of them show progression to multiple myeloma. But there is no clear indicators predicting this progression. In this study, MUC1 expression was evaluated in Pm cases to determine the predictive value and was compared with histopathologic grade which is known to be a prognostic indicator in Pm. Nine of 31 cases with Pm showed MUC1 expression. Only two of the 18 cases with mature morphology showed MUC1 expression while seven of 13 cases with immature morphology showed MUC1 expression and this was statistically significant (P<0.006). Additionally, four of 11 cases with BM involvement showed MUC1 expression while five of 20 cases without BM involvement showed MUC1 expression. There was a trend MUC1 expression with BM involvement but there was not statistically significant association between MUC1 expression and BM involvement. We found that MUC1 expression is associated with immature morphology which is an important prognostic indicator in Pm and by analogy MUC1 expression may be an additional prognostic indicator in patients with Pm.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226518     DOI: 10.1016/s0145-2126(00)00111-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  MUC1-C drives MYC in multiple myeloma.

Authors:  Ashujit Tagde; Hasan Rajabi; Audrey Bouillez; Maroof Alam; Reddy Gali; Shannon Bailey; Yu-Tzu Tai; Teru Hideshima; Kenneth Anderson; David Avigan; Donald Kufe
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

2.  Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Authors:  Michal Bar-Natan; Dina Stroopinsky; Katarina Luptakova; Maxwell D Coll; Arie Apel; Hasan Rajabi; Athalia R Pyzer; Kristen Palmer; Michaela R Reagan; Myrna R Nahas; Rebecca Karp Leaf; Salvia Jain; Jon Arnason; Irene M Ghobrial; Kenneth C Anderson; Donald Kufe; Jacalyn Rosenblatt; David Avigan
Journal:  Br J Haematol       Date:  2017-01-20       Impact factor: 6.998

3.  Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function.

Authors:  Li Yin; Rehan Ahmad; Michio Kosugi; Turner Kufe; Baldev Vasir; David Avigan; Surender Kharbanda; Donald Kufe
Journal:  Mol Pharmacol       Date:  2010-05-05       Impact factor: 4.436

4.  Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.

Authors:  Li Yin; Michio Kosugi; Donald Kufe
Journal:  Blood       Date:  2011-11-23       Impact factor: 22.113

5.  Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

Authors:  Michael Hundemer; Stefanie Schmidt; Maud Condomines; Alaviana Lupu; Dirk Hose; Marion Moos; Friedrich Cremer; Christian Kleist; Peter Terness; Sebastian Belle; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Olaf Christensen
Journal:  Exp Hematol       Date:  2006-04       Impact factor: 3.084

6.  MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.

Authors:  A R Pyzer; D Stroopinsky; J Rosenblatt; E Anastasiadou; H Rajabi; A Washington; A Tagde; J-H Chu; M Coll; A L Jiao; L T Tsai; D E Tenen; L Cole; K Palmer; A Ephraim; R K Leaf; M Nahas; A Apel; M Bar-Natan; S Jain; M McMasters; L Mendez; J Arnason; B A Raby; F Slack; D Kufe; D Avigan
Journal:  Leukemia       Date:  2017-05-30       Impact factor: 11.528

Review 7.  MUC1 and MUC2 in pancreatic neoplasia.

Authors:  E Levi; D S Klimstra; A Andea; O Basturk; N V Adsay
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

8.  MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells.

Authors:  Takeshi Kawano; Rehan Ahmad; Hiroko Nogi; Naoki Agata; Kenneth Anderson; Donald Kufe
Journal:  Int J Oncol       Date:  2008-07       Impact factor: 5.650

9.  Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma.

Authors:  Ashujit Tagde; Tahireh Markert; Hasan Rajabi; Masayuki Hiraki; Maroof Alam; Audrey Bouillez; David Avigan; Kenneth Anderson; Donald Kufe
Journal:  Oncotarget       Date:  2017-08-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.